WINNING HEALTH TECHNOLOGY GROUP CO., LTD. Financials Winning Health Technology Group Co., Ltd.
Equities
300253
CNE1000016F5
IT Services & Consulting
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.33 CNY | -2.47% |
|
-1.86% | -11.96% |
| Apr. 26 | Winning Health Technology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | UBS Upgrades China's 2024 GDP Growth Forecast | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,584 | 37,343 | 35,967 | 21,932 | 15,340 | 13,576 | - | - |
| Enterprise Value (EV) 1 | 24,094 | 36,569 | 35,293 | 21,693 | 15,323 | 13,535 | 13,493 | 13,287 |
| P/E ratio | 61.1 x | 76.2 x | 95.2 x | 203 x | 44.1 x | 24.8 x | 19.6 x | 15.2 x |
| Yield | 0.17% | 0.14% | 0.12% | 0.1% | 0.28% | 0.47% | 0.53% | 0.79% |
| Capitalization / Revenue | 12.9 x | 16.5 x | 13.1 x | 7.09 x | 4.85 x | 3.71 x | 3.06 x | 2.7 x |
| EV / Revenue | 12.6 x | 16.1 x | 12.8 x | 7.01 x | 4.84 x | 3.7 x | 3.04 x | 2.65 x |
| EV / EBITDA | 51.7 x | 59.3 x | 75.8 x | 147 x | 30.3 x | 18.1 x | 14.8 x | 12.4 x |
| EV / FCF | 576,149,507 x | 179,824,589 x | 429,490,677 x | -97,322,918 x | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | -0% | - | - | - | - |
| Price to Book | 6.59 x | 8.28 x | 7.2 x | 4.41 x | 2.77 x | 2.19 x | 2 x | 1.77 x |
| Nbr of stocks (in thousands) | 2,133,437 | 2,133,857 | 2,145,993 | 2,133,473 | 2,133,481 | 2,144,667 | - | - |
| Reference price 2 | 11.52 | 17.50 | 16.76 | 10.28 | 7.190 | 6.330 | 6.330 | 6.330 |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,908 | 2,267 | 2,750 | 3,093 | 3,163 | 3,656 | 4,436 | 5,020 |
| EBITDA 1 | 465.6 | 616.4 | 465.6 | 147.7 | 505.9 | 749.2 | 913.8 | 1,069 |
| EBIT 1 | 412.5 | 551.7 | 374.7 | 39.5 | 341.4 | 563.2 | 726.2 | 905 |
| Operating Margin | 21.62% | 24.34% | 13.62% | 1.28% | 10.79% | 15.41% | 16.37% | 18.03% |
| Earnings before Tax (EBT) 1 | 412.6 | 546.2 | 373.2 | 38.54 | 340.7 | 608.3 | 748.9 | 936.3 |
| Net income 1 | 398.4 | 491.1 | 378.2 | 108.4 | 358 | 554.9 | 699.1 | 893.6 |
| Net margin | 20.88% | 21.67% | 13.75% | 3.51% | 11.32% | 15.18% | 15.76% | 17.8% |
| EPS 2 | 0.1885 | 0.2297 | 0.1761 | 0.0506 | 0.1631 | 0.2557 | 0.3229 | 0.4160 |
| Free Cash Flow | 41.82 | 203.4 | 82.17 | -222.9 | - | - | - | - |
| FCF margin | 2.19% | 8.97% | 2.99% | -7.21% | - | - | - | - |
| FCF Conversion (EBITDA) | 8.98% | 32.99% | 17.65% | - | - | - | - | - |
| FCF Conversion (Net income) | 10.5% | 41.41% | 21.73% | - | - | - | - | - |
| Dividend per Share 2 | 0.0192 | 0.0250 | 0.0200 | 0.0100 | 0.0200 | 0.0300 | 0.0333 | 0.0500 |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 987.2 | 445.5 | 650.4 | 1,096 | 775 | 1,222 | 449.2 | 742.7 | 709.1 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 37.37 | -24.8 | -108.1 | 54.66 | 124.8 |
| Operating Margin | - | - | - | - | 4.82% | -2.03% | -24.06% | 7.36% | 17.59% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | 118.5 | 31.76 | 35.13 | 66.9 | - | - | - | - | - |
| Net margin | 12% | 7.13% | 5.4% | 6.1% | - | - | - | - | - |
| EPS 2 | - | - | - | - | 0.0400 | -0.0200 | -0.0296 | 0.0400 | 0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/22/22 | 4/22/22 | 8/26/22 | 8/26/22 | 10/26/22 | 4/18/23 | 4/24/23 | 8/17/23 | 10/25/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 489 | 774 | 674 | 239 | 17 | 40.4 | 82.5 | 289 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 41.8 | 203 | 82.2 | -223 | - | - | - | - |
| ROE (net income / shareholders' equity) | 11.7% | 12.5% | 7.45% | 2.15% | 6.65% | 8.76% | 10% | 11.2% |
| ROA (Net income/ Total Assets) | 8.52% | 8.79% | 5.58% | 1.42% | - | 6.27% | 6.8% | 7.75% |
| Assets 1 | 4,678 | 5,588 | 6,777 | 7,659 | - | 8,855 | 10,281 | 11,530 |
| Book Value Per Share 2 | 1.750 | 2.110 | 2.330 | 2.330 | 2.590 | 2.880 | 3.170 | 3.590 |
| Cash Flow per Share 2 | 0.1100 | 0.1800 | 0.1700 | 0.0500 | 0.0900 | 0.3000 | 0.2500 | 0.3300 |
| Capex 1 | 191 | 187 | 286 | 323 | 313 | 292 | 340 | 376 |
| Capex / Sales | 10.04% | 8.23% | 10.4% | 10.45% | 9.9% | 7.98% | 7.66% | 7.49% |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.33
CNY
Average target price
8.914
CNY
Spread / Average Target
+40.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.96% | 1.87B | |
| -12.82% | 192B | |
| +1.48% | 169B | |
| +4.35% | 157B | |
| +7.95% | 103B | |
| +34.09% | 82.8B | |
| +12.44% | 82.82B | |
| -5.04% | 73.21B | |
| -22.32% | 51.79B | |
| -8.25% | 44.01B |
- Stock Market
- Equities
- 300253 Stock
- Financials Winning Health Technology Group Co., Ltd.
